The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.

The company will be the first to integrate whole genome sequencing (WGS) into Epic's Aura platform, further advancing access ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 million for the fourth quarter ...